

---

**NAME: Matthew H. G. Katz, MD, CMQ, FACS, FASCO**  
**INSTITUTION: MD Anderson Cancer Center**  
**OPEN SEAT: Society Board of Directors Designated Surgical Oncologist**

---

**A. EDUCATION, POSTDOCTORAL TRAINING, LICENSURE & CERTIFICATION**

**Education:**

1999 M.D. New York Medical College, Alpha Omega Alpha, New York, NY  
1994 B. A. University of California, Berkeley (Economics), CA

**Postgraduate Training:**

2021 Analyst, Vizient, Inc., Chicago, IL  
2018-2019 Executive Education, Graduate Certificate in Health Care Management, Rice University, Houston, TX  
2017-2018 Leadership Development, MD Anderson Faculty Leadership Academy, Houston, TX  
2017-2018 Leadership Development, American Society of Clinical Oncology Leadership Development Program, Alexandria, VA  
2006-2008 Clinical Fellowship, Surgical Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, Steven Curley, MD  
2002-2006 Postdoctoral Researcher, Moores Comprehensive Cancer Center, University of California, San Diego, CA, Michael Bouvet, MD  
2000-206 Categorical Residency, General Surgery, University of California, San Diego, CA, David Easter  
1999-2000 Clinical Internship, General Surgery, University of California, San Diego, CA, David Easter

---

**B. APPOINTMENTS (Since 2015), PROFESSIONAL MEMBERSHIPS AND ACTIVITIES**

**Primary Appointments:**

Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Department Chair, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

**Academic Appointments:**

2020- Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX  
2015-2020 Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

**Administrative Appointments/Responsibilities (Selected):**

2021- Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX  
2020- Service Line Co-Leader, GI Service Line, The University of Texas MD Anderson Cancer Center, Houston, TX  
2019- Clinical Medical Director, Gastrointestinal Center, The University of Texas MD Anderson

2019-	Cancer Center, Houston, TX Division Quality Officer, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
2017-2019	Vice Chair for Research, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
2017-	Co-Leader, Pancreatic Cancer Moonshot, The University of Texas MD Anderson Cancer Center, Houston, TX
2014-2017	Surgical Oncology EHR Provider Officer, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

**Professional Memberships/Activities (edited for ASCO):**

*Society of Surgical Oncology*

2022-	Member, Quality Committee
2017-2020	Member, Quality Committee
2014-2017	Member, Training Committee
2011-2012	Member, Government Affairs Committee
2008-	Member

*National Cancer Institute Pancreas Cancer Task Force*

2017-	Member
2010-2011	Junior Investigator

*Alliance for Clinical Trials in Oncology*

2017-	GI/Pancreas Committee Co-lead
2016-	Young Investigator Committee Co-Chair
2015-	ACS-CPR Education Committee Member
2014-	ACS-CPR Executive Committee Member
2014-	ACS-CPR Cancer Care Standards Development Committee Chair
2013-2014	Study Concept Review Committee
2012-	ACS-CPR Cancer Care Standards Development Committee-Pancreas Co-Chair
2012-	ACOSOG CCOP Pancreases Prevention Team
2011-	Member, Gastrointestinal Committee
2011-	Member

*Americas Hepatopancreatobiliary Association*

2020-	Chair, Clinical Trials Committee
2017-2019	Member, Clinical Trials Committee
2014-2016	Member, Program Committee
2011-	Member
2011-2013	Member, Research Committee

*American College of Surgeons*

2011-	Fellow
-------	--------

*American Society of Clinical Oncology*

2020-2021	Leader, Gastrointestinal cancer-GE, pancreatic and HPB track leader
2018-	Member, Annual Meeting Scientific Committee
2018-	GPGC Liaison to Cancer Education Committee
2018	Member, Adjuvant Therapy for Biliary Tract Cancers Expert Panel
2017-2018	Leadership Development Program
2016-2020	Co-Chair, Gastrointestinal Advisory Group of Guidelines Committee
2014-2015	Leader, CEC Gastrointestinal Cancer-Non-Colorectal Track
2014-	Co-Chair, Resectable Pancreatic Cancer Guideline Panel
2013-2015	Member, CEC Gastrointestinal Cancer-Non-Colorectal Track
2012-	Member, Cancer Education Committee
2012-	Member

*American College of Surgeons Commission on Cancer*

2018-2020	Chair, Standards Revision Project Workgroup V
-----------	---

*American College of Surgeons Cancer Surgery Standards Program, Chicago, IL*

---

**C. RESEARCH (since 2015), EDITORIAL AND REVIEW ACTIVITIES**
**Grants and Contracts:***Funded:*

- 2018-2020 Co-Principal Investigator, 7%, PancFit: Do angiogenic biomarkers correlate with improved progression free survival in pancreatic cancer?, 1 R21 CA218732-01A1, NIH/NCI, NIH/NCI, PI - Schadler, Katz, Ngo-Huang, \$275,000
- 2016-2021 Co-Investigator, 2%, A Clinical Validation Center for Early Detection of Pancreatic Cancer, 1U01CA200468-01, NIH/NCI, PI - Anirban Maitra, \$3,005,829 (\$612,611/year)
- 2015-2020 Co-Investigator, 1%, Imaging and Molecular Correlates of Progression in Cystic Neoplasms of the Pancreas, 1U01CA196403, NIH/NCI, PI - Maitra, \$650,395

*Completed:*

- 2017-2018 Principal Investigator, Effect of preoperative exercise on physical function, quality of life and chemodelivery in patients with pancreatic cancer, The Mike Hogg Fund, \$16,000
- 2016-2018 Principal Investigator, 2%, Preoperative Extended Chemotherapy Vs. Chemotherapy Plus Hypofractionated Radiation Therapy For Borderline Resectable Adenocarcinoma Of The Head Of The Pancreas, N/A, National Pancreas Foundation, \$50,000 (\$50,000/year)
- 2016-2019 Co-Investigator, 5%, Exosomal DNA as a surrogate biomarker for early diagnosis and therapeutic stratification in pancreatic cancer, RP160517, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Anirban Matira, \$847,343 (\$283,400/year)

**Protocols:***Funded:*

- 2016- Study Chairman, Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas, ALLIANCE A021501, Alliance for Clinical Trials in Oncology
- 2015- Co-Principal Investigator, A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy in combination with MK-3475 (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer, 2015-0064, Merck

**Editor/Service on Editorial Board(s) (selected):**

- 2021- Editorial Board member, Annals of Surgery
- 2018-2023 Editorial Board Member, Journal of Clinical Oncology
- 2015- Editorial Board member, Journal of Gastrointestinal Surgery
- 2014-2020 Editorial Board member, Annals of Surgical Oncology

---

**D. AWARDS AND HONORS (Since 2017)**

- 2021- Fellow of the American Society of Clinical Oncology, American Society of Clinical Oncology
- 2019 President's Faculty Excellence Award in Quality Improvement, UT MD Anderson Cancer Center
- 2019- 2019 Top Performer (top 10% nationally on CAHPS measurers related to care experience), MD Anderson

---

**E. BIBLIOGRAPHY**
**Peer-Reviewed Original Research Articles (since 2017 – selected – of 285 total):**

1. Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MH. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. *Annals of Surgical Oncology* 24(7):2031-2039, 1/2017. PMID: 28124275.
2. Denbo JW, Slack RS, Bruno M, Cloyd JM, Prakash L, Fleming JB, Kim MP, Aloia TA, Vauthey JN, Lee JE, Katz MH. Selective Perioperative Administration of Pasireotide is More Cost-Effective Than Routine Administration for Pancreatic Fistula Prophylaxis. *J Gastrointest Surg* 21(4):636-646. e-Pub 1/2017. PMID: 28050766..
3. Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. *Br J Cancer* 116(6):697-702. e-Pub 2/2017. PMID: 28183138.
4. Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz MH. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. *Journal of Clinical Oncology* 35(20):2324-2328, 4/2017. PMID: 28398845.
5. Khorana AA, Mangu PB, Katz MH. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. *Journal of Oncology Practice* 13(6):388-391, 4/2017. PMID: 28406730.
6. Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundhani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Brennan L, Feng E, Taguchi I, Janout V, Firpo MA, Mulvihill SJ, Katz MH, Hanash SM. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. *Journal of the National Cancer Institute* 109(4), 4/2017. PMID: 28376157.
7. Chatterjee D, Katz MH, Foo WC, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, Wang H. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy. *American Journal of Surgical Pathology* 41(8):1097-1104, 6/2017. PMID: 28614206..
8. Katz MHG, Ou, Fang-Shu, Herman JM, Ahmad S, Wolpin B, Marsh R, Shi Q, Chuong M, Schwarz LH, Frankel W, Collisson E, Koay E, Hubbard J, Leenstra JL, Meyerhardt J, O'Reilly E. Alliance for Clinical Trials in Oncology (Alliance) Trial A021501: Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. *BMC Cancer* 17(1):505, 7/2017. PMID: 28750659.
9. Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. *JAMA Surgery* 152(11):1048-1056, 7/2017. PMID: 28700784.
10. Ngo-Huang AT, Parker NH, Wang X, Petzel MQB, Fogelman D, Schadler KL, Bruera E, Fleming JB, Lee JE, Katz MHG. Home based exercise during preoperative therapy for pancreatic cancer. *Langenbeck's Archives of Surgery* 402(8):1175-1185, 7/2017. PMID: 28710540.
11. Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaïss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M, Chatman K, Johnston SE, Mosher CM, Brandis A, Fuks G, Gurbatri C, Gopalakrishnan V, Kim M, Hurd MW, Katz M, Fleming J, Maitra A, Smith DA, Skalak M, Bu J, Michaud M, Trauger SA, Barshack I, Golan T, Sandbank J, Flaherty KT, Mandinova A, Garrett WS, Thayer SP, Ferrone CR, Huttenhower C, Bhatia SN, Gevers D, Wargo JA, Golub TR, Straussman R. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. *Science* 357(6356):1156-1160, 9/2017. PMID: 28912244.
12. Cloyd JM, Nogueras-Gonzalez GM, Prakash LR, Petzel MQB, Parker NH, Ngo-Huang AT, Fogelman D, Denbo JW, Garg N, Kim MP, Lee JE, Tzeng CWD, Fleming JB, Katz MHG. Anthropometric changes in patients with pancreatic ductal adenocarcinoma undergoing preoperative therapy and pancreatoduodenectomy. *Journal of Gastrointestinal Surgery* 22(4):703-712, 11/2017.
13. Cloyd JM, Katz MHG, Wang H, Cuddy A, You YN. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma. *JAMA Surgery* 152(11):1086-1088, 11/2017. PMID: 28793134.
14. Isaji S, Mizuno S, Windsor JA, Bassi C, Fernández-Del Castillo C, Hackert T, Hayasaki A, Katz MHG, Kim SW, Kishiwada M, Kitagawa H, Michalski CW, Wolfgang CL. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. *Pancreatology* 18(1):2-11, 11/2017. PMID: 29191513.
15. Amer AM, Zaid M, Chaudhury B, Elganainy D, Lee Y, Wilke CT, Cloyd J, Wang H, Maitra A, Wolff RA, Varadhachary G, Overman MJ, Lee JE, Fleming JB, Tzeng CW, Katz MH, Holliday EB, Krishnan S, Minsky BD, Herman JM, Taniguchi CM, Das P, Crane CH, Le O, Bhosale P, Tamm EP, Koay EJ. Imaging-based biomarkers: changes in the tumor interface of pancreatic ductal adenocarcinoma on CT scans indicate response to cytotoxic therapy. *Cancer* 124(8):1701-1709, 1/2018. PMID: 29370450.

16. Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM, Huang J, Wang H, Momin AA, Jacamo RO, Katz M, Wolff R, Javle M, Varadhachary G, Wistuba II, Hanash S, Maitra A, Alvarez H. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. *Annals of Oncology* 29(1):223-229, Jan 1 2018, 1/2018. PMID: 29045505.
17. Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, Wistuba II, Katz M, Varadhachary G, Park Y, Hicks J, Chinnaiyan A, Scampavia L, Spicer T, Gerhardinger C, Maitra A, Tuveson D, Rinn J, Lizee G, Yee C, Levine AJ. Dynamic changes during the treatment of pancreatic cancer. *Oncotarget* 9(19):14764-14790, 2/2018. PMID: 29599906.
18. Wang YN, Lee HH, Chou CK, Chen CT, Yang WH, Yao J, Wei Y, Lim SO, Ye Y, Hsu J, Tsou PH, Ko HW, Liu X, Liu CG, Ying H, Wu X, Wang H, Li D, Fogelman D, Katz MH, Javle M, Maitra A, Hung MC. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. *Cancer Cell* 33(4):752-769, 3/2018. PMID: 29606349.
19. Cloyd JM, Nogueras-González GM, Prakash LR, Petzel MQB, Parker NH, Ngo-Huang AT, Fogelman D, Denbo JW, Garg N, Kim MP, Lee JE, Tzeng CD, Fleming JB, Katz MHG. Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. *Journal of Gastrointestinal Surgery* 22(4):703-712, 4/2018. PMID: 29230694.
20. Cloyd JM, Omichi K, Mizuno T, Kawaguchi Y, Tzeng CD, Conrad C, Chun YS, Aloia TA, Katz MHG, Lee JE, Halperin D, Yao J, Vauthey JN, Dasari A. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. *Annals of Surgical Oncology* 25(6):1709-1715, 4/2018. PMID: 29626307.
21. Denbo JW, Bruno M, Dewhurst W, Kim MP, Tzeng CW, Aloia TA, Soliz J, Speer BB, Lee JE, Katz MHG. Risk-stratified clinical pathways decrease the duration of hospitalization and costs of perioperative care after pancreatectomy. *Surgery* 164(3):424-431, 5/2018. PMID: 29807648.
22. Lee Y, Cristini V, Lowengrub JS, Kang Y, San Lucas FA, Hobbs BP, Ye R, Eganainy D, Almahariq M, Amer AM, Yu S, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss K, Chauhan A, Zaid MM, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MHG, Wang H, Bhosale P, Tamm EP, Fleming JB. A visually apparent and quantifiable CT imaging feature identifies biophysical subtypes of pancreatic ductal adenocarcinoma. *Clinical Cancer Research* 24(23):5883-5894, 8/2018. PMID: 30082477.
23. Bernard V, Kim D, San Lucas FA, Castillo J, Allenson K, Mulu F, Stephens B, Huang J, Semaan A, Guerrero P, Kamyabi N, Zhao J, Hurd M, Koay E, Taniguchi C, Javle M, Wolff R, Katz MHG, Varadhachary G, Maitra A, Alvarez H. Circulating Nucleic Acids Associate with Outcomes of Patients with Pancreatic Cancer. *Gastroenterology* 156(1):108-118, 9/2018. PMID: 30240661.
24. Gulhati P, Prakash L, Katz MHG, Wang X, Javle M, Shroff R, Fogelman D, Lee JE, Tzeng CW, Lee JH, Weston B, Tamm E, Bhosale P, Koay EJ, Maitra A, Wang H, Wolff RA, Varadhachary GR. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. *Annals of Surgical Oncology* 26(2):619-627, 10/2018. PMID: 30324485.
25. Bannon S, Montiel M, Goldstein J, Dong W, Mork M, Borrás E, Varadhachary G, Maitra A, Katz M, Feng L, Futteral A, Fogelman D, Vilar E, Hasanov M, McAllister F. High prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. *Cancer Prevention Research* 11(11):679-686, 10/2018. PMID: 30274973.
26. Parker N, Ngo-Huang A, Lee RE, O'Connor DP, Basen-Engquist K, Petzel MQB, Wang X, Xiao L, Fogelman DR, Scbadler KL, Simpson RJ, Fleming JB, Lee JE, Varadhachary GR, Sahai SK, Katz MHG. Physical activity and exercise during preoperative pancreatic cancer treatment. *Supportive Care in Cancer* 27(6):2275-2284, 10/2018. e-Pub 10/2017. PMID: 30334105.
27. Cloyd JM, Prakash L, Vauthey JN, Aloia TA, Chun YS, Tzeng CW, Kim MP, Lee JE, Katz MHG. The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinoma. *American Journal of Surgery* 218(1):145-150, 10/2018. PMID: 30224070.
28. Bernard V, Semaan A, Huang J, San Lucas FA, Mulu FC, Stephens BM, Guerrero PA, Huang Y, Zhao J, Kamyabi N, Sen S, Scheet P, Taniguchi CM, Tzeng CW, Katz M, Singhi A, Maitra A, Alvarez H. Single Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression. *Clin Cancer Res* 25(7):2194-2205, 11/2018. PMID: 30385653.
29. Bednarski BK, Slack RS, Katz M, You YN, Papadopolous J, Rodriguez-Bigas MA, Skibber JM, Matin SF, Chang GJ. Assessment of Ileostomy Output Using Telemedicine: A Feasibility Trial. *Diseases of the Colon and Rectum* 61(1):77-83, 2018. PMID: 29215474.
30. Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Tee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and

- pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. *Proceedings of the National Academy of Sciences of the United States of America* 116(5):1692-1697, 1/2019. PMID: 30635425.
31. Capello M, Vykoukal JV, Katayama H, Bantis LE, Wang H, Kundnani DL, Aguilar-Bonavides C, Aguilar M, Triphthi SC, Dhillon DS, Momin AA, Peters H, Katz MH, Brand R, Firpo MA, Mulvihill SJ, Molldrem JJ, Feng Z, Taguchi A, Maitra A, Hanash SM. Exosomes are enriched in B cell immune response targets in pancreatic adenocarcinoma and exert a decoy function against complement-mediated cytotoxicity. *Nature Communications* 10(1):254, 1/2019. PMID: 30651550.
  32. Cloyd JM, Chen HC, Wang X, Tzeng CD, Kim MP, Aloia TA, Vauthey JN, Lee JE, Katz MHG. Chemotherapy vs Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis. *Pancreas* 48(2):216-222, 2/2019. PMID: 30629022.
  33. Wang EM, Akasaka H, Zhao J, Varadhachary GR, Lee JE, Maitra A, Fleming JB, Hung MC, Wang H, Katz MHG. Expression and Clinical Significance of Protein Kinase RNA-Like Endoplasmic Reticulum Kinase and Phosphorylated Eukaryotic Initiation Factor 2 $\alpha$  in Pancreatic Ductal Adenocarcinoma. *Pancreas* 48(3):323-328. e-Pub 2/2019.
  34. Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. *Journal of Clinical Oncology* 37(12):1015-1027, 3/2019. PMID: 30856044.
  35. Ngo-Huang A, Holmes HM, des Bordes JKA, Parker NH, Fogelman D, Petzel MQB, Song J, Bruera E, Katz MHG. Association between frailty syndrome and survival in patients with pancreatic adenocarcinoma. *Cancer Medicine* 8(6):2867-2876, 4/2019. PMID: 31033241.
  36. Bhutani MS, Cazacu IM, Luzuriaga Chavez AA, Singh BS, Wong FCL, Erwin WD, Tamm EP, Mathew GG, Le DB, Koay EJ, Taniguchi CM, Minsky BD, Pant S, Tzeng CD, Koong AC, Varadhachary GR, Katz MHG, Wolff RA, Fogelman DR, Herman JM. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. *VideoGIE* 4(5):223-225, 4/2019. PMID: 31065616.
  37. Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Panizza A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Koerkamp BG. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. *Journal of the National Cancer Institute*, 5/2019. PMID: 31086963.
  38. Khorana AA, McKernin SE, Katz MHG. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update Summary. *Journal of Oncology Practice* 15(8):454-457, 7/2019. PMID: 31306038.
  39. Perri G, Prakash L, Wang H, Bhosale P, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay E, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. *Annals of Surgery*, 7/2019. PMID: 31274655.
  40. Koay EJ\*, Katz MHG\*, Wang H, Wang X, Prakash L, Javle M, Shroff R, Fogelman D, Avila S, Zaid M, Elganainy D, Lee Y, Crane C, Krishnan S, Das P, Fleming JB, Lee JE, Tamm EP, Bhosale P, Lee JH, Weston B, Maitra A, Wolff RA, Varadhachary GR, \*Koay and Katz participated equally. *Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. JCO Precision Oncology*, 8/2019. PMCID: PMC7446521.
  41. Khorana AA, McKernin SE, Berlin J, Hong TS, Maitra A, Moravek C, Mumber M, Schulick R, Zeh HJ, Katz MHG. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. *Journal of Clinical Oncology* 37(23):2082-2088, 8/2019. PMID: 31180816.
  42. Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, Scheet P, Xu H, Hanash SM, Feng L, Burks JK, Do KA, Peterson CB, Nejman D, Tzeng CD, Kim MP, Sears CL, Ajami N, Petrosino J, Wood LD, Maitra A, Straussman R, Katz M, White JR, Jenq R, Wargo J, McAllister F. Tumor Microbiome Diversity and Composition Determine Pancreatic Cancer outcomes. *Cell* 178(4):795-806, 8/2019. PMID: 31398337.
  43. Florez Bedoya CA, Cardoso ACF, Parker N, Ngo-Huang A, Petzel MQ, Kim MP, Fogelman D, Romero SG, Wang H, Park M, Katz MHG, Schadler KL. Exercise during preoperative therapy increases tumor vascularity in pancreatic tumor patients. *Scientific Reports* 9(1):13966, 9/2019. PMID: 31562341.
  44. Parker NH, Lee RE, O'Connor DP, Ngo-Huang A, Petzel MQB, Schadler K, Wang X, Xiao L, Fogelman D, Simpson R, Fleming JB, Lee JE, Tzeng CWD, Sahai SK, Basen-Engquist K, Katz MHG. Supports and barriers to home-based physical activity during preoperative treatment of pancreatic cancer: a mixed-methods study. *Journal of physical activity and health*, 10/2019. PMID: 31592772.
  45. Ngo-Huang A, Parker NH, Bruera E, Lee RE, Simpson R, O'Connor DP, Petzel MQB, Fontillas RC, Schadler K, Xiao L, Wang X, Fogelman D, Sahai SK, Lee JE, Basen-Engquist K, Katz MHG. Home-Based Exercise

- Prehabilitation During Preoperative Treatment for Pancreatic Cancer Is Associated With Improvement in Physical Function and Quality of Life. *Integrative Cancer Therapies*, 12/2019. PMID: 31858837.
46. Prakash LR, Wang H, Zhao J, Nogueras-Gonzalez GM, Cloyd JM, Tzeng CD, Kim MP, Lee JE, Katz MHG. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. *J Gastrointest Surg* 24(2):368-379, 2/2020. e-Pub 2/2019. PMID: 30820801.
  47. Capello M, Fahrman JF, Rios Perez MV, Vykoukal JV, Irajizad E, Tripathi SC, Roife D, Bantis LE, Kang Y, Kundnani DL, Xu H, Prakash LR, Long JP, Katayama H, Fleury A, Ferri-Borgogno S, Baluya DL, Dennison JB, Aguilar Bonavides C, Casabar JP, Celiktas M, Do K, Fiehn O, Maitra A, Wang H, Feng Z, Chiao PJ, Katz MH, Fleming JB, Hanash SM. CES2 expression is predictive of response to irinotecan and is associated with type 2 diabetes. *JCO Precision Oncology* 4:426-436, 4/2020.
  48. Perri G, Prakash L, Malleo G, Caravati A, Varadhachary GR, Fogelman D, Pant S, Koay EJ, Herman J, Maggino L, Milella M, Kim M, Ikoma N, Tzeng CW, Salvia R, Lee JE, Bassi C, Katz MHG. The sequential radiographic effects of preoperative chemotherapy and (chemo)radiation on tumor anatomy in patients with localized pancreatic cancer. *Annals of Surgical Oncology*, 4/2020. PMID: 32266574.
  49. Zhao B, Blair SL, Katz MHG, Lowy AM, Kelly KJ. Adherence with operative standards in the treatment of gastric cancer in the United States. *Gastric Cancer* 23(3):550-560, 5/2020. e-Pub 11/2019. PMID: 31745679.
  50. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. *Ann Surg* 271(6):996-1002, 6/2020. PMID: 31895709.
  51. Lillemoe HA, Newhook TE, Aloia TA, Grubbs EG, Chang GJ, Katz MHG, Vauthey JN, Lee JE, Tzeng CWD. Perceptions of Opioid Use and Prescribing Habits in Oncologic Surgery: A Survey of the Society of Surgical Oncology Membership. *Journal of Surgical Oncology*, 7/2020. PMID: 32632993.
  52. Keung EZ, Asare EA, Chiang YJ, Prakash LR, Rajkot N, Torres KE, Hunt KK, Feig BW, Cormier JN, Roland CL, Katz MHG, Lee JE, Tzeng CD. Postoperative pancreatic fistula after distal pancreatectomy for non-pancreas retroperitoneal tumor resection. *Am J Surg* 220(1):140-146, 7/2020. e-Pub 11/2019. PMCID: PMC7652036.
  53. Ikoma N, Kim MP, Zeng CDT, Tran Cao HS, Lee JE, Katz MH. External Retraction Techniques for Robotic Pancreatoduodenectomy. *Journal of the American College of Surgeons*, 8/2020. PMID: 32805403.
  54. Newhook TE, Soliz JM, Prakash LR, Hancher-Hodges S, Speer BB, Wilks JA, Ikoma N, Kim MP, Lee JE, Katz MHG, Tzeng CD. Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma. *Annals of Surgical Oncology*, 8/2020. PMID: 32803553.
  55. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Response to and survival after first-line FOLFIRINOX or gemcitabine/nab-paclitaxel for localized pancreatic ductal adenocarcinoma. *JAMA Surg* 155(9):832-839, 9/2020. PMCID: PMC7364337.
  56. Tzeng CW, Tran Cao H, Roland CL, Teshome M, Bednarski BK, Ikoma N, Graham PH, Zeung EEZ, Scally CP, Katz MHG, Gershenwald JE, Lee JE, Vauthey JN. Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approach. *Journal of Surgical Oncology* 34:182-185, 9/2020. PMID: 32891326.
  57. Datta J, Wilson GC, D'Angelica MI, Katz MHG, Maithe SK, Merchant NB, Ahmad SA. A Call for Caution in Overinterpreting Exceptional Outcomes Following Radical Surgery for Pancreatic Cancer: Let the Data Speak. *Annals of Surgery*, 10/2020. PMID: 33086320.
  58. Wei D, Zaid, MM, Katz MH, Prakash LR, Kim M, Tzeng CD, Lee JE, Agrawal A, Rashid A, Wang H, Varadhachary G, Wolff R, Tamm EP, Bhosale PR, Maitra A, Koay EJ, Wang E. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. *Pancreatol*, 11/2020.
  59. Ngo-Huang A, Herbert A, Fontillas RC, Parker NH, Asumbrado R, Garg N, Dibaj S, Liu D, Guo Y, Shin KY, Katz MHG, Bruera E. Frequency of sarcopenia, sarcopenic obesity, and changes in physical function in surgical oncology patients referred for prehabilitation. *Integrative Cancer Therapies*, 20, 1/2021. PMID: 33829906.
  60. Parker NH, Gorzelitz J, Ngo-Huang A, Caan BJ, Prakash L, Garg N, Petzel MQB, Schadler K, Basen-Engquist K, Katz MHG. The role of home-based exercise in maintaining skeletal muscle during preoperative pancreatic cancer treatment. *Integrative Cancer Therapies* 20, 1/2021. PMID: 33870744.
  61. Parker NH, Basen-Engquist K, Rubin ML, Li Y, Prakash L, Ngo-Huang A, Gorzelitz J, Ikoma N, Lee JE, Katz MHG. Factors influencing exercise following pancreatic tumor resection. *Annals of Surgical Oncology* 28(4):2299-2309, 4/2021. PMID: 32886288.
  62. Marchegiani G, Pollini T, Andrianello S, Tomasoni G, Biancotto M, Javed AA, Kinny-Köster B, Amini N, Han Y, Kim H, Kwon W, Kim M, Perri G, He J, Bassi C, Goh BK, Katz MH, Jang JY, Wolfgang C, Salvia R.

- Progression vs Cyst Stability of Branch-Duct Intraductal Papillary Mucinous Neoplasms After Observation and Surgery. *JAMA Surg.* e-Pub 5/2021. PMID: PMC8135059.
63. Nissen AP, Vreeland TJ, Teshome M, Archer MA, Francescatti AB, Katz MHG, Hunt KK, Zheng L, Mullett TW. American College of Surgeons Commission on Cancer Standard for Curative Intent Pulmonary Resection. *Annals of Thoracic Surgery*, 6/2021. PMID: 34119494.
  64. Semaan A, Bernard V, Kim DU, Lee JJ, Huang J, Kamyabi N, Stephens BM, Qiao W, Varadhachary GR, Katz MH, Shen Y, San Lucas FA, Gascoyne P, Alvarez HA, Maitra A, Guerrero PA. Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer. *Br J Cancer* 124(12):1970-1977, 6/2021. e-Pub 3/2021. PMID: PMC8185080.
  65. Le O, Javadi S, Bhosale PR, Koay EJ, Katz MH, Sun J, Yang W, Tamm EP. CT Features Predictive of Nodal Positivity at Surgery in Pancreatic Cancer Patients Following Neoadjuvant Therapy in the Setting of Dual Energy CT Abdominal Radiology. *Abdom Radiol (NY)* 46(6):2620-2627, 6/2021. e-Pub 1/2021. PMID: 33471129.
  66. Allen CJ, Eska JS, Thaker NG, Feeley TW, Kaplan RS, Huey RW, Tzeng CD, Lee JE, Frank SJ, Aloia TA, Gottumukkala V, Katz MHG. Developing a Value Framework: Utilizing Administrative Data to Assess an Enhanced Care Initiative. *J Surg Res* 262:115-120, 6/2021. e-Pub 2/2021. PMID: 33561722.
  67. Deng J, Kang Y, Cheng CC, Li X, Dai B, Katz MH, Men T, Kim MP, Koay E, Huang H, Brekkan RA, Fleming JB. Cancer cell-derived DDR1 mediates collagen type 1-induced neutrophil extracellular traps to promote metastasis in pancreatic ductal adenocarcinoma. *JCI Insight*, 7/2021. PMID: 34237033.
  68. Hester CA, Kothari AN, Mason M, Maxwell J, Ikoma N, Kim MP, Tzeng CD, Lee JE, Katz MHG, Cao HST. Surgical eligibility does not imply surgical equity: recommendations for curative treatment in patients with stage I/II pancreatic head adenocarcinoma differ by age and race. *Annals of Surgery*, 7/2021. PMID: 34183508.
  69. Kim BJ, Newhook TE, Blumenthaler A, Chiang YJ, Aloia TA, Roland CL, Katz MHG, Vauthey JN, Lee JE, Tzeng CD. Sustained reduction in discharge opioid volumes through provider education: Results of 1168 cancer surgery patients over 2 years. *J Surg Oncol* 124(1):143-151, 7/2021. e-Pub 3/2021. PMID: 33751605.
  70. Wörmann SM, Zhang A, Thege FI, Cowan RW, Rupani DN, Wang R, Manning SL, Gates C, Wu W, Levin-Klein R, Rajapakshe KI, Yu M, Multani AS, Kang Y, Taniguchi CM, Schlacher K, Bellin MD, Katz MHG, Kim MP, Fleming JB, Gallinger S, Maddipati R, Harris RS, Notta F, Ross SR, Maitra A, Rhim AD. APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. *Nature Cancer* 2(12):1338-1356, 12/2021. PMID: 35121902.
  71. Allen CJ, Thaker NG, Prakash L, Kruse BC, Feeley TW, Kaplan RS, Huey R, Frank SJ, Aloia TA, Gottumukkala V, Katz MHG. Communicating value: Use of a Novel Framework in the Assessment of an Enhanced Recovery Initiative. *Annals of Surgery* 273(1):e7-e9, jan 1, 12/2021. PMID: 32568750.
  72. Newhook TE, Prakash LR, Soliz J, Hancher-Hodges S, Speer BB, Wilks JA, Bruno ML, Dewhurst WL, Arvide EM, Maxwell JE, Ikoma N, Kim MP, Lee JE, Katz MHG, Tzeng CD. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. *Journal of Surgical Oncology* 124(8):1381-1389, 12/2021. PMID: 34398988.
  73. Newton AD, Newhook TE, Bruno ML, Prakash L, Chiang YJ, Arango NP, Dewhurst WL, Arvide EM, Ikoma N, Maxwell JE, Kim MP, Lee JE, Katz MHG, Tzeng CD. Iterative Changes in Risk-Stratified Pancreatectomy Clinical Pathways and Accelerated Discharge After Pancreaticoduodenectomy. *Journal of Gastrointestinal Surgery*, 1/2022. PMID: 35023033.
  74. Douglas JE, Liu S, Ma J, Wolff RA, Pant S, Maitra A, Tamm EP, Bhosale P, Katz MHG, Varadhachary GR, Koay EJ. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. *BMC Cancer* 22(1):14, 1/2022. PMID: 34980020.
  75. Janssen QP, van Dam JL, Doppenberg D, Prakash LR, van Eijck CHJ, Jarnagin WR, O' Reilly EM, Panizza A, Besselink MG, Katz MHG, Tzeng CD, Wei AC, Zureikat AH, Groot Koerkamp B; Trans-Atlantic Pancreatic Surgery (TAPS) Consortium. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium. *Journal of the National Cancer Institute*, 2/2022. PMID: 35157075.
  76. Bagley AF, Ludmir EB, Maitra A, Minsky BD, Li Smith G, Das P, Koong AC, Holliday EB, Taniguchi CM, Katz MHG, Tamm EP, Wolff RA, Overman MJ, Patel S, Kim MP, Tzeng CD, Ikoma N, Bhutani MS, Koay EJ. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. *Clinical and translational radiation oncology*(33):66-69, 2/2022. PMID: 35097226.
  77. Hirata Y, Katz MHG, Ikoma N. Robotic Duodenojejunostomy Bypass for Metastatic Pancreatic Body Cancer. *Journal of Gastrointestinal Surgery*, 2/2022. PMID: 35132565.
  78. Katz MHG, Francescatti AB, Hunt KK; Cancer Surgery Standards Program of the American College of Surgeons. Technical Standards for Cancer Surgery: Commission on Cancer Standards 5.3-5.8. *Annals of Surgical Oncology*, 2/2022. PMID: 35187620.
  79. Uppal A, Kothari AN, Scally CP, Roland CL, Bednarski BK, Katz MHG, Vauthey JN, Chang GJ; D3CODE Team. Adoption of Telemedicine for Postoperative Follow-Up After Inpatient Cancer-Related Surgery. *JCO Oncology Practice*, 3/2022. PMID: 35263166.



80. Witt RG, Newhook TE, Prakash LR, Bruno ML, Arvide EM, Dewhurst WL, Ikoma N, Maxwell JE, Kim MP, Lee JE, Katz MHG, Tzeng CD. Association of Patient Controlled Analgesia and Total Inpatient Opioid Use After Pancreatectomy. *Journal of Surgical Oncology* 275:244-251, 3/2022. PMID: 35306260.
81. Elsherif SB, Javadi S, Le O, Lamba N, Katz MHG, Tamm EP, Bhosale PR. Baseline CT-based Radiomic Features Aid Prediction of Nodal Positivity after Neoadjuvant Therapy in Pancreatic Cancer. *Radiology: Imaging Cancer* 4(2):e210068, 3/2022. PMID: 35333131.
82. DiPeri TP, Newhook TE, Day RW, Chiang YJ, Dewhurst WL, Arvide EM, Bruno ML, Scally CP, Roland CL, Katz MHG, Vauthey JN, Chang GJ, Badgwell BD, Perrier ND, Grubbs EG, Lee JE, Tzeng CD. A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients. *Surgery Open Science* 9:51-57, Apr 25, 4/2022. PMID: 35663797.
83. Allen CJ, Smith GL, Prakash L, Volk RJ, Ikoma N, Aloia TA, Gottumukkala V, Katz MHG. What is "Value"? Results of a Survey of Cancer Patients and Providers. *Annals of Surgical Oncology*, 4/2022. PMID: 35391609.
84. Kim BJ, Arvide EM, Gaskill C, Martin AN, Kawaguchi Y, Chiang YJ, Dewhurst WL, Phan TL, Tran Cao HS, Chun YS, Katz MHG, Vauthey JN, Tzeng CD, Newhook TE. Comparative analysis of opioid use between robotic and open pancreatoduodenectomy. *Surgery Open Science*, 5/2022. PMID: 35747509.
85. Newton AD, Newhook TE, Bruno ML, Prakash L, Chiang YJ, Arango NP, Dewhurst WL, Arvide EM, Ikoma N, Maxwell JE, Kim MP, Lee JE, Katz MHG, Tzeng CD. Contemporary Assessment of Need for Palliative Bypass After Aborted Pancreatoduodenectomy Following Neoadjuvant Therapy. *Journal of Gastrointestinal Surgery* 26(5):1054-1062, May 2022, 5/2022. PMID: 35023033.
86. Kurz E, Hirsch CA, Dalton T, Shadaloey SA, Khodadadi-Jamayran A, Miller G, Pareek S, Rajaei H, Mohindroo C, Baydogan S, Ngo-Huang A, Parker N, Katz MHG, Petzel M, Vucic E, McAllister F, Schadler K, Winograd R, Bar-Sagi D. Exercise-induced engagement of the IL-15/IL-15R $\alpha$  axis promotes anti-tumor immunity in pancreatic cancer. *Cancer Cell*, May 31, 5/2022. PMID: 35660135.
87. Wang CX, Elganainy D, Zaid MM, Butner JD, Agrawal A, Nizzero S, Minsky BD, Holliday EB, Taniguchi CM, Smith GL, Koong AC, Herman JM, Das P, Maitra A, Wang H, Wolff RA, Katz MH, Crane CH, Cristini V, Koay EJ. Mass transport model of radiation response: calibration and application to chemoradiation for pancreatic cancer. *International Journal of Radiation Oncology, Biology, Physics*, May 25, 5/2022. PMID: 35643254.
88. DiPeri TP, Newhook TE, Tran Cao HS, Ikoma N, Dewhurst WL, Arvide EM, Bruno ML, Katz MHG, Vauthey JN, Lee JE, Tzeng CD. Opioid Discharge Prescriptions After Inpatient Surgery: Risks of Rebound Refills by Length of Stay. *Journal of Surgical Research*, May 18, 5/2022. PMID: 35597025.
89. Kim BJ, Arvide EM, Gaskill C, Martin AN, Kawaguchi Y, Chiang YJ, Dewhurst WL, Phan TL, Tran Cao HS, Chun YS, Katz MHG, Vauthey JN, Tzeng CD, Newhook TE. Risk-stratified posthepatectomy pathways based upon the Kawaguchi-Gayet complexity classification and impact on length of stay. *Surgery Open Science* 9:109-116, May 8, 5/2022. PMID: 35747509.
90. Adams AM, Vreeland TJ, Teshome M, Francescatti AB, Zheng L, Hunt KK, Katz MHG, Messick CA. American College of Surgeons Commission on Cancer Standard 5.7 for Total Mesorectal Excision for Mid-to-Low Rectal Cancer. *Journal of the American College of Surgeons* 234(6):1249-1253, June 1, 2022, 6/2022. PMID: 35703824.
91. Monberg ME, Geiger H, Lee JJ, Sharma R, Semaan A, Bernard V, Wong J, Wang F, Liang S, Swartzlander DB, Stephens BM, Katz MHG, Chen K, Robine N, Guerrero PA, Maitra A. Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution. *Nature Communications* 13(1):3652, June 25, 6/2022. PMID: 35752636.
92. DiPeri TP, Newhook TE, Prakash LR, Ikoma N, Maxwell JE, Kim MP, Lee JE, Katz MHG, Tzeng CD. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first. *Journal of Surgical Oncology*, 6/2022. PMID: 35726394.
93. Lee JH, Yu AC, Ali FS, Ahmed O, Lynch P, Ge P, Coronel E, Kim M, Coronel M, Folloder J, Katz MHG. The conundrum in endoscopic management of duodenal polyps: a tertiary cancer center experience. *Expert Review of Gastroenterology and Hepatology*, 6/2022. PMID: 35687675.
94. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, Ahmad S, Marsh R, Schwartz L, Behr S, Frankel WL, Collisson E, Leenstra J, Williams TM, Vaccaro G, Venook A, Meyerhardt JA, O'Reilly EM. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. *JAMA Oncology*, July 14, 2022, 7/2022. PMID: 35834226.
95. Koay EJ, Zaid M, Aliru M, Bagereka P, Van Wieren A, Rodriguez MJ, Jacobson G, Wolff RA, Overman M, Varadhachary G, Pant S, Wang H, Tzeng CW, Ikoma N, Kim M, Lee JE, Katz MH, Tamm E, Bhosale P, Taniguchi CM, Holliday EB, Smith GL, Ludmir EB, Minsky BD, Crane CH, Koong AC, Das P, Wang X, Javle M, Krishnan S. Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in

- Treating Patients with Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase I Trial and Imaging-based Biomarker Validation. *Int J Radiat Oncol Biol Phys*, July 18, 2022, 7/2022. PMID: 35863672.
96. Janssen QP, van Dam JL, Prakash LR, Doppenberg D, Crane CH, van Eijck CHJ, Ellsworth SG, Jarnagin WR, O'Reilly EM, Panizza A, Reyngold M, Besselink MG, Katz MHG, Tzeng CD, Zureikat AH, Groot Koerkamp B, Wei AC; Trans-Atlantic Pancreatic Surgery (TAPS) Consortium. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. *Journal of the National Comprehensive Cancer Network* 20(7):783-791, 7/2022. PMID: 35830887.
97. Schalck A, Sakellariou-Thompson D, Forget MA, Sei E, Hughes TG, Reuben A, Bai S, Hu M, Kumar T, Hurd MW, Katz MHG, Tzeng CD, Pant S, Javle M, Fogelman DR, Maitra A, Haymaker CL, Kim MP, Navin NE, Bernatchez C. Single cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer. *Cancer Discovery*, July 18, 2022, 7/2022. PMID: 35849783.

#### **Books (edited and written):**

1. Multiple authors. Ed(s) Katz MH, Ahmad S. *Multimodality Management of Borderline Resectable Pancreatic Cancer*. Springer, 2015.
2. Multiple authors. Ed(s) Nelson H, Hunt KK, Veeramachaneni N, Blair S, Chang G, Halverson A, Katz MH, Posner MC. *Operative Standards for Cancer Surgery*. 1. Wolters Kluwer: Philadelphia, 2015.
3. Multiple authors. Ed(s) Hunt K, Katz MH. *Operative Standards for Cancer Surgery*. Series Ed(s) Katz MH. 2. Walters Kluwer: Philadelphia, 2018.

#### **Conferences and Symposia:**

*Presentations at National or International Conferences (since 2017)*  
*Invited (since 2015)*

Katz MH. Treatment sequencing for borderline and locally advanced pancreatic cancer, Americas Hepatopancreatobiliary Association, Miami, FL, 3/10/2018

Katz MH. How do I navigate through the national and local infrastructure of clinical trials research?, Society of Surgical Oncology, Chicago, IL, 3/24/2018

Katz MH. Pancreatic Tumors: The Surgeon's Perspective, Cancer Imaging and Intervention, Houston, TX, 4/5/2018

Katz MH. Rationale for neoadjuvant therapy, Pancreas 2018, Baltimore, MD, 5/28/2018

Katz MH. Techniques of vascular resection for pancreatic cancer, 4th International HPB Surgery Forum, Hangzhou, China, 6/15/2018

Katz MH. Borderline resectable pancreatic cancer, 4th International HPB Surgery Forum, Hangzhou, China, 6/16/2018

Katz MH. Neoadjuvant chemo for resectable PDAC: Yes, 4th International HPB Surgery Forum, Hangzhou, China, 6/16/2018

Katz MH. Pancreas Cases, MD Anderson-CHUV Symposium, Lausanne, Switzerland, 9/3/2018

Katz MH. Tumor board-best practices for case presentation: Pancreas, American College of Surgeons Cancer Programs Conference, Chicago, IL, 9/6/2018

Katz MH. Improving care with operative standards, American College of Surgeons Cancer Programs Conference, Chicago, IL, 9/7/2018

Katz MH. Assessing treatment response and determining surgical approach in the era of TNT for locally advanced PDAC, Society of Surgical Oncology, San Diego, CA, 3/28/2019

Katz MH. Treatment of pancreatic exocrine insufficiency, AbbVie, Association of Physician Assistants in Oncology, Houston, TX, 4/27/2019

Katz MH. Borderline resectable pancreatic cancer: history and current state, Pancreas Club, San Diego, CA, 5/18/2019

Katz MH. Introduction to the operative standards for cancer surgery, American College of Surgeons Quality and Safety Conference, Washington, DC, 7/20/2019

Katz MH. Gastrointestinal Cancers- Noncolorectal, American Society of Clinical Oncology- Best of ASCO, Baltimore, MD, 8/2/2019

Katz MH. Vascular resections in pancreatic surgery, Society of Clinical Surgery, Edinburgh, Scotland, 9/6/2019

Katz MHG. Role of Surgery in Locally Advanced Disease Following Neoadjuvant Therapy, International Society of Gastrointestinal Oncology, Washington, DC, 10/11/2019

Katz MH. Can you meet the operative standards? Synoptic reporting, American College of Surgeons Commission on Cancer, San Francisco, CA, 10/27/2019

Katz MH. Clinical trial designs including novel technology and window trials, American College of Surgeons, San Francisco, CA, 10/27/2019

Katz MH. Correlative aspects: QOL, PRO, Imaging, Pathology Assessments in Clinical Trials, American College of Surgeons, San Francisco, CA, 10/27/2019

Katz MH. Cancer surgery and quality of care standards, American College of Surgeons, San Francisco, CA, 10/30/2019

Katz MH. Borderline resectable pancreatic cancer, 2nd MD Anderson International Meeting in Gastrointestinal Oncology, Madrid, Spain, 11/15/2019

Katz MH. Neoadjuvant therapy is needed in resectable pancreatic cancer: NO!, 2nd MD Anderson International Meeting in Gastrointestinal Oncology, Madrid, Spain, 11/15/2019

Katz MHG. Total neoadjuvant vs. adjuvant therapy for resectable pancreatic cancer TNT (sort of...), Great Debates and Updates Gastrointestinal Malignancies, Virtual, 3/19/2021

Katz MH. Evidence based management of locally advanced pancreatic cancer, Americas Hepatopancreatobiliary Association, Miami (Virtual), 8/3/2021

Katz MH. AHPBA Mentorship Program, Americas Hepatopancreatobiliary Association, Miami (Virtual), 8/4/2021

*Other, Including Scientific Exhibitions (since 2017)*

Katz MH. All suspected mucinous cystic neoplasms should be resected, Americas Hepatopancreatobiliary Association, Miami, FL, 3/30/2017

Katz MH. Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas, Americas Hepatopancreatobiliary Association, Miami, FL, 3/31/2017

Katz MH. Physical activity is associated with improved quality of life and functional fitness among patients receiving preoperative therapy for pancreatic cancer, 52nd Annual Meeting of the Pancreas Club, Washington, DC, 6/1/2018

Katz MHG. Locally advanced cancer of the esophagogastric junction, Japan Society of Surgical Oncology, Yokohama, Japan, 11/19/2018

Katz MH. Perioperative clinical trials for NET: challenges and opportunities, International Workshop on Multiple Endocrine Neoplasia, Houston, TX, 3/27/2019

Katz MH. Optimizing sequence and combination of multidisciplinary care for borderline resectable PDAC, American Society of Clinical Oncology, Chicago, IL, 6/3/2019

Katz MH. Preoperative therapy for borderline resectable pancreatic cancer, Surgical Biology Club II, San Francisco, CA, 10/27/2019

Katz MH. Carbohydrate loading and immunonutrition, MD Anderson ERAS Symposium, Houston, TX, 2/21/2020

Katz MHG. Monitoring response on preoperative therapy, Americas Hepatopancreatobiliary Association, Miami, FL, 3/2020

Katz MHG. National Webinar: Operative Standards for Cancer Surgery: Standards 5.3 - 5.8, American College of Surgeons, Webinar, 7/9/2020

Katz MHG. National Webinar: Cancer Surgery Standards Program Launch, American College of Surgeons, 7/22/2020

Katz MHG. Surgical Update in Pancreatic Cancer, Atrium Health Fall Foliage Cancer Conference, Virtual, 10/1/2020

Katz MHG. Updates in the treatment of localized pancreatic cancer, International Society of Gastrointestinal Oncology, Virtual, 10/1/2020

Katz MHG. Borderline resectable pancreatic cancer: where have we been and where are we going, American College of Surgeons, Virtual, 10/5/2020

Katz MHG. Total neoadjuvant vs. adjuvant therapy for resectable pancreatic cancer: Adjuvant!, Great debates and updates in gastrointestinal malignancy, Virtual, 10/24/2020

Katz MHG. Case discussion: pancreatic cancer, International Hepatopancreatobiliary Association, Virtual, 11/29/2020

Katz MH, Shi Q, Meyers JP, Herman JM, Chuong M, Wolpin BM, Ahmad S, Marsh R, Schwartz LH, Behr S, Frankel WL, Collisson EA, Leenstra JL, Williams TM, Vaccaro GM, Venook AP, Meyerhardt JA, O'Reilly EM. Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas, American Society of Clinical Oncology, Virtual, 1/17/2021

Katz MH. Surgery perspective: FOLFIRINOX for all?, American Society of Clinical Oncology, Virtual, 1/17/2021

Katz MHG. Fulfilling the Operative Standards and Pathology Reporting Standard 5.7 and Standard 5.8, ACS Cancer Programs: Quality Cancer Care in Motion Conference, American College of Surgeons, Virtual, 4/28/2021

Katz MHG. Total neoadjuvant vs. adjuvant therapy for resectable pancreatic cancer TNT (sort of...), Great Debates in Gastrointestinal Malignancies, Virtual, 5/7/2021

Katz MHG. The rollout and implementation of the synoptic operative reports: goals, pitfalls and lessons learned, American College of Surgeons Cancer Integration Conference, Virtual, 5/20/2021

Katz MH. Optimal strategy for borderline resectable pancreatic cancer, Americas Hepatopancreatobiliary Association, Miami (Virtual), 8/2/2021

Harris JB, Katz MHG, Baker TP. Operative standards 5.1, 5.3-5.6 and resources, American College of Surgeons, Virtual, 11/3/2021

Katz MHG. PREOPANC-4: Locally advanced pancreatic cancer, Dutch PREOPANC-4, Virtual, Netherlands, 12/1/2021

Katz MHG. Mesopancreatic resection, 10th Brazilian Congress on Liver, Pancreas and Biliary Surgery, Virtual, Brazil, 12/3/2021

Katz MHG. Alliance A021501 and beyond, Society of Surgical Oncology, Dallas, TX, 3/11/2022

Katz MHG. Is there a role for radiation in borderline resectable pancreatic cancer? NO, Great Debates and Updates in Gastrointestinal Malignancies, New York, NY, 3/26/2022

Katz MHG. Neoadjuvant therapy for resectable pancreatic cancer: YES, 15th IHPBA World Congress, New York, NY, 4/2/2022

Katz MHG. Anticoagulation After Vascular Resection at Pancreatectomy, Pancreas Club, San Diego, CA, 5/21/2022

#### *Seminar Invitations from Other Institutions (since 20170*

Progress in Surgical Oncology: Lessons from Harvey, The Ohio State University, Surgery, Columbus, OH, 7/1/2018

Multimodality therapy for localized pancreatic cancer: where have we been and where are we going?, Our Lady of the Lake Medical Center, Baton Rouge, LA, 11/18/2019

Best Neoadjuvant Strategy for Resectable Pancreatic Cancer, University of Toronto, Toronto, Canada, 3/5/2021

#### *Lectureships and Visiting Professorships*

Multimodality therapy for potentially curable pancreatic cancer The Surgeon's Role, Ruth E. and Robert M. Moore Lecture, University of Texas Medical Branch, Surgery, Galveston, TX, 6/27/2018

Multimodality therapy for localized pancreatic cancer: Lessons from Harvey, 1st Annual Alumni Lecture, University of California San Diego, Surgery, San Diego, CA, 3/13/2019

Multimodality therapy for localized pancreatic cancer: where have we been and where are we going?, University of Toronto, Surgical Oncology, Toronto, Ontario, Canada, 6/13/2019

Multimodality therapy for localized pancreatic cancer: where have we been and where are we going?, Lefcourt Family Cancer Center, Englewood Hospital and Medical Center, Englewood, NJ, 11/7/2019

Localized pancreatic cancer: where have we been and where are we going?, Boyce Family Visiting Lectureship, University of Cincinnati, Surgery, Cincinnati, OH, 4/27/2022